Evidence map›Paper›PMID 39651244›Full record

ArticlebioRxiv : the preprint server for biology2024

HyperMPNN-A general strategy to design thermostable proteins learned from hyperthermophiles.

Moritz Ertelt, Phillip Schlegel, Max Beining, Leonard Kaysser, Jens Meiler, Clara T Schoeder

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Moritz ErteltInstitute for Drug Discovery, Leipzig University, Faculty of Medicine, Leipzig, Germany.ORCID 0009-0004-2506-6660
Phillip SchlegelInstitute for Drug Discovery, Leipzig University, Faculty of Medicine, Leipzig, Germany.ORCID 0009-0006-4640-2322
Max BeiningInstitute for Drug Discovery, Leipzig University, Faculty of Medicine, Leipzig, Germany.
Leonard KaysserInstitute for Drug Discovery, Leipzig University, Faculty of Medicine, Leipzig, Germany.ORCID 0000-0002-3943-993X
Jens MeilerInstitute for Drug Discovery, Leipzig University, Faculty of Medicine, Leipzig, Germany.ORCID 0000-0001-8945-193X
Clara T SchoederInstitute for Drug Discovery, Leipzig University, Faculty of Medicine, Leipzig, Germany.ORCID 0000-0002-4664-961X

Funding

Decrypting Variants of Uncertain Significance in Long-QT SyndromeR01HL122010 · NHLBI · VANDERBILT UNIVERSITY · PI GEORGE, ALFRED L., SANDERS, CHARLES R · 2014 to 2025
$15.5M
Cerebrovascular involvement in Alzheimer's Disease: PAR4 AntagonismR01AG068623 · NIA · VANDERBILT UNIVERSITY · PI HAMM, HEIDI E, MEILER, JENS · 2024 to 2025
$1.4M
Personalized Structural Biology: Enabling Exome Interpretation in Undiagnosed DiseasesR01LM013434 · NLM · VANDERBILT UNIVERSITY · PI CAPRA, JOHN ANTHONY, MEILER, JENS · 2021 to 2024
$1.4M
GPU-Accelerated Parallel Computer for Life Sciences ResearchS10OD032234 · OD · VANDERBILT UNIVERSITY · PI SMITH, JARROD ANSON · 2022 to 2022
$600k
Parallel Computer with High Memory NodesS10OD016216 · OD · VANDERBILT UNIVERSITY · PI PISTON, DAVID W · 2013 to 2013
$598k
GPU-Accelerated Parallel Computer for Drug Discovery ApplicationsS10OD020154 · OD · VANDERBILT UNIVERSITY · PI SMITH, JARROD ANSON · 2015 to 2015
$225k
NHLBI NIH HHS R01 HL122010NIA NIH HHS R01 AG068623NIH HHS S10 OD016216NIH HHS S10 OD020154NIH HHS S10 OD032234NLM NIH HHS R01 LM013434
6 · The paper itself

Abstract

Stability is a key factor to enable the use of recombinant proteins in therapeutic or biotechnological applications. Deep learning protein design approaches like ProteinMPNN have shown strong performance both in creating novel proteins or stabilizing existing ones. However, it is unlikely that the stability of the designs will significantly exceed that of the natural proteins in the training set, which are biophysically only marginally stable. Therefore, we collected predicted protein structures from hyperthermophiles, which differ substantially in their amino acid composition from mesophiles. Notably, ProteinMPNN fails to recover their unique amino acid composition. Here we show that a retrained network on predicted proteins from hyperthermophiles, termed HyperMPNN, not only recovers this unique amino acid composition but can also be applied to proteins from non-hyperthermophiles. Using this novel approach on a protein nanoparticle with a melting temperature of 65°C resulted in designs remaining stable at 95°C. In conclusion, we created a new way to design highly thermostable proteins through self-supervised learning on data from hyperthermophiles.

Identifiers

PMID39651244
PMCPMC11623624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.